ipl-logo

Midwest Laboratories Spin Off Case

580 Words3 Pages

On January 01, 2013, Abbott Laboratories spin off its one of the businesses (pharmaceutical business) into a completely new publically traded company: AbbVie Inc. The new company was expected to be the key growth driver for the parent company. There was a spin off because of many reasons. According to the chief executive officer of the company, Miles White, it was more of a fundamental change. The pharmaceutical sector is quite risky given the fact that there is huge volatility in the cash flows for the company. Due to the patents and other such intellectual property issues, the company is never termed as stable and hence the parent company has the risk of losing the path in the midway. But there was a risk too because of this. Most of the cash flow for the parent company comes from the pharmaceutical business and hence a spin off might mean lowering of cash flows and the impact could be seen in the top and the bottom line for the company. …show more content…

Sometimes, it is considered to be one of the most successful [spinoffs] in the market. At the time of the spin off there was a huge capital crunch for the company. They needed huge capital inflows for their main business and hence to maintain the core competency in the business they spin off the business. This is in contrast to many of the businesses in the industry who try to sell off their business segments. But as per the CEO of the company for the same you would need to look out for the buyer in the market and then agree to a price which is quite difficult than the spin

Show More
Related
534 Words | 3 Pages

The diversification lowered the overall risk of the firm and created an information network among the divisions, which was critical for the company to gain competitive advantage. The loyal customer base was another strength. The $60 billion assets that under the company’s management provided the company a positive brand image and made it easier for the company to attract new customers. Weakness:

Read More
1980 Words | 8 Pages

One of the main featured taking their four regional units and turning them into global business units or GBUs. Outsourcing these GBUs into business divisions that handled the work of the main business helped promote innovation. After the stock fell from $86 to $60 per share in January 2000, it was important for them to strategize. Confidence was an issue with this company from the get go and resulted in lots of problems, so a shake up was needed. The case for global product divisions was based on innovation and duplicating those functions across research facilities would hold them accountable.

Read More
663 Words | 3 Pages

The water industry was an instance where the company decided to sell out because it had limited potential. Rick Priory stated Duke Energy is defined by what it does not do. Duke Energy remains focused rather than being drawn into new fads. The trend Duke Energy has followed is investing in solid companies with steady returns (McNulty, Plodding Duke).

Read More
595 Words | 3 Pages

Over the years, the company has invested in building a strong brand portfolio, which helps when you want to expand into new product categories. Other strengths include a strong dealer community who not only sell the drugs, but train their sales team on how to inform the customer on the benefits. Lastly, strong free cash flow, good returns on capital expenditure, and a successful track record shows that the company can provide resources for new projects and build new revenue streams. One weakness of the company is poor financial planning. Their financial planning is not done properly or efficiently and the company could use its cash more efficiently than its doing as of right now.

Read More
1553 Words | 7 Pages

As a result, HCA sold its non-hospital businesses and several facilities that did not meet with this new strategy and focus. In 1999 HCA also completed additional spin-offs known as LifePoint and Triad Hospital groups. In 2006 HCA returned to being a private company. This was down after completing another merger in which the company was acquired by a private investor group including affiliates of Bain Capital, Kohlberg Kravis Roberts & Co., and Merrill Lynch Global Private Equity.

Read More
1051 Words | 5 Pages

They didn’t want to lose out on any profits by going global. Since they were new to this line of business they partner with J&J’s McNeil division. J&J were an excellent choice to partner with to introduce Benecol to the global market. The only hurdles stopping Benecol to be introduced into the world were regulatory issues. It would be difficult to bring Benecol to the market as quickly as possible in Europe and even more so in US.

Read More
915 Words | 4 Pages

This led to the downfall of Phycor, Inc. (Burns, L. R., Bradley, E.H., & Weiner, B.J., 2011). Most of the health care companies were bankrupt and were on the verge of shutting down their operations, however, Phycor wanted to take this as a competitive advantage to acquire competitors and other small clinics. Once Phycor announced their offer to buy MedPartners, Inc. their share went down by 10 percent and people lost trust due to their significant strategic and operational strategies (Burns, L. R., Bradley, E.H., & Weiner, B.J., 2011).

Read More
522 Words | 3 Pages

But the company should not just hold it and do not make more benefits. A private equity firm could purchase all of Bellamy’s outstanding shares at a price higher than $16.25 per share, its current stock price. It would then

Read More
825 Words | 4 Pages

The goal is to make a lifechanging medication at an affordable price. Also, owning a lot of patents under their name has helped them earn a lot of profits. The Merck company has succeeded in differentiating itself as cost leadership

Read More
991 Words | 4 Pages

As a result of this rapid success, John created a spin-off company

Read More
690 Words | 3 Pages

The validity of the reasoning for each reason from each separate enterprise seemed logical and positive from both, but as much as it was good to focus on how they could benefit there didn’t seem to be much consideration of other factors. These factors being risk, consideration and alignment of goals, overall business plan, how each operates, or additional research of each’s separate market and how it will affect the other (tying again into risk). The perspective appears to focus on separate positives versus overall collaborative entrepreneurship, just how they can use the other to their benefit, which seems naïve and not well thought through (Carayannis, Samara, & Bakouros, 2015). They were surprised to learn that developing a successful drug and bringing it to market, after its potential was identified, could cost up to $500 million because they did not do their research or consult Sterling regarding this process. They didn’t make an informed, evidence and research

Read More
1245 Words | 5 Pages

• Highly profitable business. • Robustly developed sales and distribution network. Weaknesses • Heavy investment in R&D. • High marketing and communication costs. • There are cities in where they are not present yet (like Montrose).

Read More
1156 Words | 5 Pages

The number of acquisitions is not so high and it depends more upon the organic expansion. • These pharmacies face informative and predictable risk from the variability of “generic conversion” • Inability of the company to keep stride with the growing private labeled brands popularity. • The in-store implementation of the store formats and services is not consistent at every

Read More
720 Words | 3 Pages

Many new companies to enter the market without burden of costly tasks such as research and development, clinical trials and manufacturing of drugs. Moreover, patent expiry is one of the reasons which is offering opportunities for lower cost generic manufacturer in terms of greater market access. Additionally, the government has increased their focus on healthcare cost cutting. It is creating pressure on the authority to allow early introduction of low-cost drugs in the

Read More
2104 Words | 9 Pages

INTRODUCTION The latter decade of the 20th century brought a number of major innovations to the pharmaceutical industry, most notably a remarkable wave of successful joint ventures and mergers between big and medium players in the market. In this case study we analyzed the Rorer and Rhône-Poulenc (RP) merger in July 31, 1990 that created a major multinational company: the Rhône-Poulenc Rorer, Inc. (RPR), where the RP became the majority shareholder, owning 68 percent of the RPR’s shares. Prior to the merger, Rorer lacked the resources to access the European market, and the firm presented relatively low cash balance and rising debt which, according to financial analysts, appeared to be handicapping its strategy of growth by acquisitions.

Read More

More about Midwest Laboratories Spin Off Case

Related Topics

Open Document